Intellia Therapeutics, Inc. (NTLA) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Intellia Therapeutics is a clinical-stage gene editing company focused on developing curative therapeutics using CRISPR/Cas9-based technologies. The company is advancing in vivo programs for genetic diseases (e.g., ATTR amyloidosis, hereditary angioedema) and ex vivo programs for immuno-oncology and autoimmune diseases.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $6.96 million | $13.59 million | $35.89 million | $26.20 million |
| Operating Expenses | $146.00 million | $145.93 million | $288.94 million | $270.49 million |
| Net Loss | $(146.98) million | $(123.68) million | $(254.41) million | $(226.81) million |
| Net Loss Per Share | $(1.52) | $(1.40) | $(2.64) | $(2.58) |
| Cash & Cash Equivalents | $130.85 million (as of June 30, 2024) | |||
| Marketable Securities | ||||
| Total Liquidity | $939.9 million (Cash, equivalents, and marketable securities) |
Material Changes vs. Prior Period
- Revenue Fluctuation: Q2 2024 revenue decreased 49% compared to Q2 2023, primarily due to a reduction in revenue recognized under the AvenCell license and collaboration agreement. However, YTD 2024 revenue increased 37% compared to YTD 2023, driven by the recognition of $21.0 million of previously eliminated intra-entity profit from AvenCell in Q1 2024.
- Investment Impairments: The company recorded a significant non-cash expense of $20.4 million in Q2 2024 related to the change in fair value of its investment in Kyverna Therapeutics. Additionally, a $25.3 million impairment was recorded in Q1 2024 related to the AvenCell investment following a change in accounting method from equity method to ASC 321.
- Operating Expenses: R&D expenses remained relatively flat quarter-over-quarter but increased 6% YTD, driven by higher external costs for lead programs NTLA-2001 and NTLA-2002, partially offset by a workforce reduction in January 2024.
- Financing Activity: The company raised approximately $94.4 million in net proceeds through at-the-market (ATM) offerings during the first six months of 2024.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities ($939.9 million) to fund operations and capital expenditures into late 2026, excluding potential milestone payments.
- Clinical Progress:
- NTLA-2001 (ATTR): The Phase 3 MAGNITUDE trial is enrolling ahead of projections. The company received EU approval to proceed in multiple countries.
- NTLA-2002 (HAE): Positive topline results from the Phase 2 study were announced in August 2024. The Phase 3 study is on track to initiate in the second half of 2024.
- NTLA-3001 (AATD): First-in-human Phase 1/2 study is expected to dose the first patient in the second half of 2024.
- Legal Proceedings: On July 8, 2024, BlueAllele Corp. filed a patent infringement lawsuit against Intellia regarding bi-directional insertion template technology. Intellia intends to defend the matter; potential loss is currently indeterminable.
- Risk Factors: Key risks include the unproven nature of in vivo CRISPR therapies, potential delays in clinical trials, reliance on third-party manufacturers, and intellectual property disputes (including the ongoing UC/Vienna/Charpentier vs. Broad Institute interference).
Investor Verification Checklist
- Investment Valuation: Verify the impact of the $20.4 million Kyverna fair value adjustment and the $25.3 million AvenCell impairment on future earnings volatility.
- Revenue Sustainability: Assess the sustainability of collaboration revenue given the one-time $21.0 million AvenCell profit recognition in Q1 and the subsequent decline in Q2.
- Cash Burn Rate: Monitor the net cash used in operating activities ($178.8 million YTD) against the $939.9 million liquidity runway to validate the "late 2026" funding estimate.
- Legal Exposure: Track the BlueAllele Corp. litigation for potential injunctions or damages that could impact the DNA writing technology platform.
- ATM Program: Review the remaining capacity ($331.7 million) under the amended 2022 Sale Agreement for potential future dilution.